All In MedTech

Device Trial Radar · NCT07474558

SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Oct 23, 2026

Primary completion

Jan 15, 2030

Study completion Sep 15, 2031

Sponsor

Lead sponsor
Jules Bordet InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BelleTorus Corporation; Gilead Sciences; Paxman
First posted
Mar 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to determine if scalp cooling (by the Paxman Scalp Cooling System) reduces the extent and severity of alopecia in participants with advanced solid tumours receiving ADC. The main question it aims to evaluate the efficacy of scalp cooling in reducing chemotherapy-induced alopecia in participants with advanced/metastatic solid tumours receiving antibody-drug conjugates (trastuzumab-deruxtecan, sacituzumab-govitecan, or datopotamab-deruxtecan), as assessed by blinded central dermatological review. Researchers will compare the experimental arm (ADC treatment + scalp cooling) with the control arm (ADC only). Scalp cooling will be done each day of ADC treatment : before, during and post-infusions of their ADC treatment.

Conditions

  • Advanced or Metastatic Solid Tumour
  • Antibody-Drug Conjugate
  • Alopecia

Interventions

  • scalp coolingDevice

    scalp cooling at -10°C for each cycle of ADC, subjects will ubdergo scalp cooling : 30 minutes prior ADC treatment, during ADC treatment and 90 minutes following ADC treatment

  • photographs via the Belle.AI appOther

    artificial intelligence-based software tool designed for standardised photographic documentation and automated assessment of alopecia severity using the Severity of Alopecia Tool (SALT) scale generated AI Score will be blinded for investigator and patient outcome does not impact treatment of the subject

  • Antibody-Drug ConjugatesDrug

    study will randomize female participants receiving one of the following ADCs as part of their standard-of-care treatment: sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. percentage of participants with hair lossTime frame: 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Helora - Hopital de Mons - Site Kennedy

    Mons, Belgium · Not yet recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.